The Latest Analyst Ratings For Bicycle Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Bicycle Therapeutics (NASDAQ:BCYC) over the past three months, with a majority being bullish. The average 12-month price target is $42.25, slightly down from the previous $43.50. Key analysts have maintained their ratings, with one lowering the price target. Bicycle Therapeutics has shown significant revenue growth but faces challenges in ROE and ROA.
August 07, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bicycle Therapeutics (NASDAQ:BCYC) received mixed analyst ratings with a majority being bullish. The average 12-month price target is $42.25, down from $43.50. The company has shown significant revenue growth but faces challenges in ROE and ROA.
The majority of analysts are bullish on BCYC, which is positive for short-term price movement. However, the slight decrease in the average price target and challenges in ROE and ROA may temper some of the optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100